Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07191106
Recruiting Not applicable

Pilot Study Assessing the Feasibility and Impact of a Remote Adapted Physical Activity Program on Quality of Life in Patients With Inflammatory Bowel Disease (IBD)

NCT07191106 · tracked via the Priya Life Science France tracker
Sponsor
Raincy Montfermeil Hospital Group
Phase
Not applicable
Started
2025-09-15
Last updated
2025-09-24

Condition(s) studied

Inflammatory Bowel Disease (IBD)Inflammatory Bowel Disease (Crohn&Amp;#39;s Disease and Ulcerative Colitis)

Investigational drug(s) / intervention(s)

adapted physical activity

adapted physical activity: Comparative before-and-after study over a 3-month period of remote Adapted Physical Activity (APA) delivered through the MOOV+ application

Study summary

Inflammatory Bowel Disease (IBD) is a chronic relapsing condition that affects the gastrointestinal tract and is increasingly diagnosed in adolescents and young adults. Although anti-TNFα therapies are effective in reducing disease activity and improving quality of life, they are frequently associated with side effects such as fatigue, weight gain, and joint pain, which may be mitigated by regular physical activity.

Emerging evidence suggests that light to moderate physical activity may help reduce systemic and intestinal inflammation and improve IBD-related outcomes. However, access to structured physical activity programs remains limited, and personal or professional constraints may hinder participation.

This pilot study aims to assess the feasibility and impact of a remotely delivered Adapted Physical Activity (APA) program on the quality of life of patients with Inflammatory Bowel Disease (IBD), including Crohn's disease and ulcerative colitis. This study evaluates the effects of a 12-weeks remote APA intervention on quality of life as the primary outcome.

Secondary objectives include assessing changes in anxiety and depression, fatigue levels, IBD activity, and smoking behavior. The findings from this study may inform the development of scalable, non-pharmacological strategies to support symptom management and well-being in individuals with IBD.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults aged 18 years and older * Diagnosis of Inflammatory Bowel Disease (IBD) established for at least 6 months * Patient is motivated to participate in the Adapted Physical Activity (APA) program * Medical certificate confirming fitness to engage in remote physical activity * Access to a digital device with internet connectivity enabling use of the MOOV+ application at home * Written informed consent freely given after appropriate information * Affiliation with, or beneficiary of, a national health insurance system Exclusion Criteria: * Patients under 18 years of age * Medical contraindication to physical activity * High levels of physical activity as defined by the International Physical Activity Questionnaire (IPAQ): * Total \>1500 MET-min/week of vigorous activity on at least 3 days, OR * Total physical activity \>3000 MET-min/week, regardless of distribution * Presence of psychological disorders that may interfere with study participation * Lack of access to a device or internet connection enabling remote participation * Pregnant or breastfeeding women * Patients under legal guardianship or curatorship * Patients under legal protection

Primary outcome measure(s)

  • Impact of a Remote Adapted Physical Activity Program Delivered via the MOOV+ Application on Quality of Life in Patients With Inflammatory Bowel Disease: A Pilot Before-and-After Study — From baseline (Month 0) to Month 3
    Change in total Inflammatory Bowel Disease Questionnaire (IBDQ-32) score between baseline and the end of the program at Month 3 (M3)

Trial sites (2)

FacilityCityRegionStatus
GHI Le Raincy Montfermeil Montfermeil France Recruiting
CHU Nantes Nantes France Not Yet Recruiting

Other trials for the same condition

Evaluation of a Multimodal Day Hospital for the Overall Management of Patients With Chronic Inflammatory Bowel Diseases (IBD) Starting soon
Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation Starting soon
Metabolic Reprogramming of Monocytes in Inflammatory Flares of Inflammatory Bowel Diseases Starting soon
Cohort of Patients With Ulcerative Colitis or Polyps Followed in CHU de Bordeaux Associated With a Biocollection - COLIBRI Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07191106 on ClinicalTrials.gov ↗ ← All trials in France